Ruxolitinib vs best available therapy for et intolerant or resistant to hydroxycarbamide

Claire N. Harrison, Adam J. Mead, Anesh Panchal, Sonia Fox, Christina Yap, Emmanouela Gbandi, Aimee Houlton, Samah Alimam, Joanne Ewing, Marion Wood, Frederick Chen, Jason Coppell, Nicki Panoskaltsis, Steven Knapper, Sahra Ali, Angela Hamblin, Robyn Scherber, Amylou C. Dueck, Nicholas C.P. Cross, Ruben MesaMary Frances McMullin

Research output: Contribution to journalArticlepeer-review

66 Scopus citations

Fingerprint

Dive into the research topics of 'Ruxolitinib vs best available therapy for et intolerant or resistant to hydroxycarbamide'. Together they form a unique fingerprint.

Medicine & Life Sciences

Chemical Compounds